Biopharma is entering a new kind of “cliff”—not just the patent cliff, but the operational cliff that comes with it.
When exclusivity ends, the market doesn’t simply open. It floods. Generics arrive faster, pricing compresses margins, and every week of…
Pharma executives don’t lose deals because they miss a clinical endpoint.
They lose deals because they misread the map.
Eurasia looks “familiar” on a slide deck—Russia, Turkey, Kazakhstan, Ukraine, and a patchwork of other markets that matter for reven…
Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know Read Post »
Drug patent expiry dates aren’t just legal milestones—they’re commercial deadlines. And most companies treat them like a calendar item instead of a growth strategy.
Here’s the agitation: when a patent cliff approaches, teams often scramble. Legal revie…
Turn Drug Patent Expiry Dates Into Your Next Sales Campaign Read Post »
The Smarter Monopoly? Orphan Drug Exclusivity vs. Standard Drug Patents
A lot of the debate around drug pricing sounds like a tug-of-war between innovation and affordability. But the real story is more technical—and more consequential.
In the U.S., the…
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
The hardest part of biologics isn’t the science—it’s the calendar.
Loss of exclusivity (LOE) for biologics doesn’t arrive politely. It hit…
OpenAI’s GPT just did something that should make every drug-patent strategist sit up: it’s being positioned as a tool that can “smash” drug patent cliffs—by accelerating the work that historically takes years, teams, and deep institutional know-how.
Th…
OpenAI’s GPT-Rosalind = Smashed Drug Patent Cliffs and 70% Faster ANDAs Read Post »
OpenAI’s “GPT for life sciences” headlines are everywhere. But the real question isn’t whether these models can read biomedical text—it’s whether they can change the economics of drug development.
In a recent DrugPatentWatch piece on GPT-Rosalind, the …
GPT-Rosalind: What OpenAI’s Life Sciences Model Actually Does to Drug Development Read Post »
AI is starting to “know” your drug the way your competitors do. The question is whether you’ll use that knowledge—or get outpaced by it.
In pharma, we’ve long treated competitive intelligence as a scavenger hunt: dig through labels, scour patents, map …
What AI Knows About Your Drug vs. Your Competitors Read Post »
Two systems, one fight: how the “patent dance” and Orange Book linkage are shaping the $400B biologics war
Biologics are no longer just a scientific category—they’re a battleground for market access, pricing power, and investor expectations. And behind…
AI is your drug’s new KOL—and you’re not tracking it.
For years, pharma’s “influence map” has been built around familiar nodes: key opinion leaders, conference circuits, advisory boards, and the quiet gravity of respected clinicians. But the center of …
AI Is Your Drug’s New KOL — and You’re Not Tracking It Read Post »